GSA Capital Partners LLP Sells 82,065 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

GSA Capital Partners LLP reduced its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 43.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 108,229 shares of the biotechnology company’s stock after selling 82,065 shares during the quarter. GSA Capital Partners LLP owned 0.05% of BioCryst Pharmaceuticals worth $844,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of BioCryst Pharmaceuticals by 2.2% during the 4th quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock valued at $173,732,000 after purchasing an additional 482,494 shares during the period. Deerfield Management Company L.P. grew its stake in shares of BioCryst Pharmaceuticals by 159.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after purchasing an additional 7,477,000 shares during the period. State Street Corp grew its stake in shares of BioCryst Pharmaceuticals by 8.9% during the 2nd quarter. State Street Corp now owns 8,505,392 shares of the biotechnology company’s stock valued at $76,208,000 after purchasing an additional 691,988 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in shares of BioCryst Pharmaceuticals by 22.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 5,225,986 shares of the biotechnology company’s stock valued at $39,665,000 after purchasing an additional 947,431 shares during the period. Finally, Two Sigma Investments LP grew its stake in shares of BioCryst Pharmaceuticals by 3.1% during the 3rd quarter. Two Sigma Investments LP now owns 4,419,629 shares of the biotechnology company’s stock valued at $33,545,000 after purchasing an additional 131,406 shares during the period. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Trading Down 1.0%

Shares of NASDAQ:BCRX opened at $8.29 on Friday. The stock has a 50 day moving average of $9.16 and a 200 day moving average of $7.95. The company has a market cap of $2.11 billion, a PE ratio of -4.66 and a beta of 0.57. BioCryst Pharmaceuticals, Inc. has a 12-month low of $6.00 and a 12-month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The company had revenue of $156.41 million for the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The company’s revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.20 earnings per share. Equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.66 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Alane P. Barnes sold 150,000 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $9.15, for a total value of $1,372,500.00. Following the transaction, the insider directly owned 400,703 shares of the company’s stock, valued at approximately $3,666,432.45. The trade was a 27.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 5.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on BCRX. Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Needham & Company LLC cut their price target on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Royal Bank Of Canada cut their price target on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Wedbush cut their price target on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Finally, Citizens Jmp boosted their price target on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research note on Thursday, May 7th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.70.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.